Gensia Inc., Microbix deal

GNSA's Gensia Laboratories division received U.S. marketing rights to ThromboClear, a generic equivalent to an existing acute cardiovascular drug used to treat pulmonary embolism and coronary artery thrombosis. ThromboClear contains urokinase, which aids in the dissolution of blood clots.

The proprietary product posted 1995 sales of $165 million, GNSA said. ...